Home > Dermatology > SPIN 2019 > Advances in Therapy > Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity

Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity

Expert
Dr Gayle van der Kraaij, Amsterdam UMC, the Netherlands
Conference
SPIN 2019

Dr Gayle van der Kraaij (Amsterdam UMC, the Netherlands) presented the first-year results from a Dutch/Belgian study that showed increased efficacy, adalimumab serum levels, and fewer antidrug antibodies when adalimumab is supplemented with methotrexate [1].

She explained the problem: adalimumab therapy is hampered by primary and secondary non-response. The lack of response is because in many patients only low serum drug levels can be detected, which is directly attributable to the formation of antidrug antibodies. The researchers sought to optimise adalimumab efficacy by applying a trick learned from rheumatoid arthritis, namely that the addition of methotrexate can alleviate this problem. The investigators performed a pragmatic randomised controlled trial in psoriasis patients, which was assessor-blinded in 5 hospitals in the Netherlands and Belgium. They compared adalimumab (n=30) vs adalimumab with methotrexate (10 mg/week supplemented with folic acid;...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on